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Summary: Checkpoint inhibitors have improved survival of meta-
static melanoma. However, reliable biomarkers to predict response
are still needed. Immunoglobulin G (IgG) antibody subclasses
reﬂect immunocompetence in individuals and are known to be
involved in essential functions in our immune system. This pro-
spective study evaluated the association between serum IgG with its
subclasses IgG1, IgG2, IgG3, and IgG4 and antitumor response
according to RECIST 1.1. Serum samples from 49 patients were
prospectively collected before the start of treatment with a check-
point inhibitor. We observed a statistically signiﬁcant association of
baseline IgG2 with response to therapy (P= 0.011). After deﬁning
optimal cutpoints, we found signiﬁcant associations between total
IgG (> 9.66 g/L, P= 0.038), IgG1 (> 6.22 g/L, P= 0.025), IgG2
(> 2.42 g/L, P= 0.019), and IgG3 (> 0.21 g/L, P= 0.034) with
progression-free survival. Prolonged overall survival was associated
with elevated IgG2 (> 2.42 g/L, P= 0.043). Together, these ﬁndings
deﬁne total IgG and subclasses as predictors of clinical successful
checkpoint inhibition in metastatic melanoma patients.
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C heckpoint inhibitors (CIs) have revolutionized the treat-ment of several cancer types including melanoma, which is
reﬂected in a signiﬁcantly increased patient survival. CIs targeting
the CTLA4-B7 (iplimumab) or PD1-PDL1 (nivolumab, pem-
brolizumab) axis have been approved for melanoma and show
response rates around 40% with anti-PD1monotherapy and 60%
with the combination of ipilimumab and nivolumab.1–6
Melanoma is a rather immunogenic tumor. Spontaneous
tumor regression has been reported on several occasions.
Consistently, it shows a higher incidence in immunosuppressed
patients.7,8 This implies immunosurveillance of melanoma and
likely explains the clinical effectiveness of immunomodulatory
agents including CIs in metastatic melanoma.
Total serum immunoglobulin G (IgG) levels range
from 7 to 16 g/L in normal individuals and consist of 4 IgG
subclasses. IgG1 is quantitatively the most abundant IgG
subclass known to be produced in response to soluble
antigens and membrane proteins and functions to neutralize
toxins and pathogens.9 Immunoglobulin G2 (IgG2) is pro-
duced in response to bacterial capsular polysaccharide
antigens and has the unique feature of not binding to Fc
receptors on antigen-presenting cells. Immunoglobulin G3
(IgG3) is a potent proinﬂammatory antibody but has a low
in vivo half-life explaining its relatively low abundance in
serum.10 Immunoglobulin G4 (IgG4) is thought to play an
important role in allergic reactions together with immuno-
globulin E (IgE). Unlike other IgG subclasses, it does not
activate the complement system following antigen binding
and is thus believed to act as an immune-regulatory IgG
subclass. Consistently, during desensitizing immunotherapy
to treat allergies, relief of symptoms correlates with the
emergence of allergen-speciﬁc IgG4 antibodies.11
As IgG production requires functional antigen-presenting,
T-helper and B cells, serum IgG subclass levels reﬂect the
immunocompetence of an individual. Hypogammaglobulinemia,
including selective IgG deﬁciencies, are known to result in
susceptibility for infections and are also associated with
autoimmunity.12 As checkpoint inhibition requires a functional
immune system, our hypothesis was that preexisting IgG and the
composition of the IgG subclasses might be associated with
efﬁcacy of CI therapy in patients with metastatic melanoma. The
aim of this prospective study was, therefore, to test whether
pretreatment serum IgG and IgG subclass levels (IgG1, IgG2,
IgG3, and IgG4) correlate with antitumor response and survival
following CI therapy.
MATERIALS AND METHODS
Patient Cohort
We prospectively included patients with metastatic
melanoma starting treatment with anti-PD1 or anti-CTLA4
antibodies at the Kantonsspital St. Gallen and University
Hospital Zürich.
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Patients had at least 2 treatment cycles of either nivo-
lumab (Opdivo; Bristol-Myers Squibb SA, 3 mg/kg every 2
weeks), pembrolizumab (Keytruda; MSD Merck Sharp &
Dohme AG, 2mg/kg every 3 weeks), ipilimumab (Yervoy;
Bristol-Myers Squibb SA, 3 mg/kg every 3 weeks) or the
combination of nivolumab and ipilimumab (1 and 3mg/kg
every 3 weeks). Serum samples were collected at the day of
treatment start. Computed tomographic scans (CT) were
performed after 10–12 weeks, and response was assessed
according to RECIST 1.1 criteria.13 Patients with pro-
gressive disease (PD) at the ﬁrst CT scan were conﬁrmed
with another scan after 4–6 weeks with focus on potential
pseudoprogression.14 Responders were deﬁned as complete
remission (CR) or partial remission (PR). Nonresponders
were deﬁned as stable disease (SD) or PD.
The study was approved by the local ethics committees
(EKOS 16/079, respectively, EK 647, EK800) and was
carried out in accordance with the declaration of Helsinki
principles.
Analyses of Immunoglobulins
Immunoglobulin levels were assessed by commer-
cially available immunoturbidimetric methods (Binding site,
Birmingham, UK) using an SPA plus analyzer (Binding site,
Birmingham, UK). IgG subgroup concentrations (ie, IgG1,
IgG2, IgG3, and IgG4) were determined using a Behring
nephelometer II (BNII) (Siemens Diagnostics, Zurich,
Switzerland) using reagents from Siemens (Siemens Diag-
nostics, Zurich, Switzerland). In our hands, the imprecision of
the utilized methods, as assessed by coefﬁcient of variations
(CV) obtained from serial measurements of commercially
available control materials, was as follows: 3% for total IgG
(at concentrations of 7.1 and 13.2 g/L). The respective CVs for
the IgG subgroups were as follows: 4.0% (at a concentration
of 4.63 g/L) and 2.76% (at a concentration of 8.42%) for IgG1,
4.5% (at concentrations of 2.22 and 4.06 g/L) for IgG2, 6.17%
(at a concentration of 0.22 g/L) and 5.07% (at a concentration
of 0.4 g/L) for IgG3, and 5.7% (at concentrations of 0.38 and
0.96 g/L) for IgG4.
Statistical Analyses
R software (version 3.5.0) was used for all statistical
analyses. The “survival” and “survminer” packages were
used for survival analysis.15,16
The package “maxstat” was implemented to identify
optimal cutpoints for biomarker levels that correspond to the
most signiﬁcant relation with progression-free survival (PFS)
and overall survival (OS), using the maximally selected log-
rank statistic.17 The minimal proportion (“minprop” argument)
in each group was set to 0.30. Kaplan-Meier plots were gen-
erated for OS and PFS, and the patients were categorized into
“high” and “low” groups on the basis of the optimal cutpoint
for continuous levels of total IgG and IgG subclasses. Hazard
ratios (HR) for each biomarker were calculated using Cox’s
proportional hazards model. The association between IgG
levels and PFS or OS was examined using the log-rank test.
RESULTS
A total of 49 patients were enrolled into the study.
A total of 42 (86%) patients received monotherapy with
an anti-PD1 antibody (nivolumab or pembrolizumab),
5 patients (10%) were treated with a combination of nivo-
lumab plus ipilimumab, and 2 patients (4%) received an
ipilimumab monotherapy.
One patient had a CR (2%) at the ﬁrst CT scan, 23 had
a PR (47%), 10 reached SD (20%), and 15 patients had PD
(31%). Responders (CR, PR) versus nonresponders (SD,
PD) were distributed as follows: 49% (n= 24) versus 51%
(n= 25). Detailed patient characteristics are presented in
Table 1. A total of 29 patients (59%) developed an adverse
event of any grade (8 gastrointestinal, 8 endocrine, 7 skin, 3
renal, 2 pneumonitis, and 1 hematological).
IgG2 levels before initiation of CI therapy were
signiﬁcantly higher in the responder group versus the non-
responder-group (P= 0.011). No signiﬁcant differences were
observed for total IgG, IgG1, IgG3, and IgG4 between
responders and nonresponders (Fig. 1).
TABLE 1. Patient Characteristics
Age at start of immunotherapy (y)
Median 68
Range 30–93
Sex [n (%)]
Female 23 (47)
Male 26 (53)
Histology [n (%)]
SSM 14 (29)
Nodular 17 (35)
LMM 1 (2)
Nevoid 1 (2)
Desmoplastic 1 (2)
Uveal 6 (12)
Mucosal 7 (14)
Amelanotic 2 (4)
Phototype [n (%)]
1 1 (2)
2 26 (53)
3 13 (27)
4 1 (2)
NA 8 (16)
BRAF status [n (%)]
Mutated* 13 (27)
Wild type 36 (73)
Type of immunotherapy [n (%)]
Anti-PD1 42 (86)
Anti-CTLA4 2 (4)
Anti-PD1+anti-CTLA4 5 (10)
Metastatic sites [n (%)]
1 11 (22)
2 16 (33)
3 7 (14)
4 6 (12)
5 5 (10)
6 2 (4)
7 1 (2)
8 1 (2)
Tumor response at ﬁrst CT scan [n (%)]
CR 1 (2)
PR 23 (47)
SD 10 (20)
PD 15 (31)
Treatment line [n (%)]
First line 23 (47)
Second line 21 (43)
Third line 4 (8)
Fourth line 1 (2)
*V600 mutation.
Anti-CTLA4 indicates anticytotoxic-T-lymphocyte–associated protein-4;
Anti-PD1, anti–programmed-cell-death protein-1; CR, complete remission;
CT, computed tomography; LMM, lentigo maligna melanoma; NA, not
applicable; PD, progressive disease; PR, partial remission; SD, stable disease;
SSM, superﬁcial spreading melanoma.
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Next, we evaluated whether speciﬁc levels of IgG and IgG
subclasses were associated with PFS and OS. The median
follow-up time was 20.7 months (interquartile range, 17.5–
24.3mo). For the calculated optimal cutpoints (see the Materials
and methods section), PFS was signiﬁcantly better in patients
with high levels of total IgG [>9.66 g/L, HR=0.43, conﬁdence
interval: 0.18–0.98, P=0.038], IgG1 (>6.22 g/L, HR=0.32,
conﬁdence interval: 0.11–0.92, P=0.025), IgG2 (>2.42 g/L,
HR=0.41, conﬁdence interval: 0.19–0.88, P=0.019), and
IgG3 (>0.21 g/L, HR=0.45, conﬁdence interval: 0.21–0.96,
P=0.034) (Fig. 2). Furthermore, OS was signiﬁcantly prolonged
in patients with IgG2 levels >2.42 g/L (HR=0.41, conﬁdence
interval: 0.17–1.00, P=0.043) (Fig. 3). All the signiﬁcant asso-
ciations remained such after a false discovery rate of 0.10 was
imposed using the Benjamini-Hochberg correction for multiple
comparisons.
No statistically signiﬁcant difference of IgG levels
between responders and nonresponders (St. Gallen cohort)
was seen during the course of treatment, and no statistically
signiﬁcant association was seen with adverse events.
DISCUSSION
To our knowledge, this is the ﬁrst study providing evi-
dence that baseline serum immunoglobulin levels may serve as
predictive markers for response to CI therapy. Furthermore, a
prognostic association of IgG subclass levels and survival was
demonstrated. Until now, several baseline immune blood
parameters were evaluated for their effect on response and
survival for treatment with CIs in metastatic melanoma.
Associations between better outcome and high lymphocyte
count,18–21 a low neutrophil count,22 and a low neutrophil/
lymphocyte ratio are known.23 All these results underline the
importance of T-cell activity against cancer cells. Our study
focusing on the role of humoral immunity for CI therapy
hypothesizes that B cells also may be involved.
Of note, measuring immunoglobulins in the serum is a
simple, reliable, and rather cheap procedure readily avail-
able in virtually all routine medical laboratories.
Low serum IgG2 and IgG4, but not IgG3, have been
recently shown to be associated with the clinical diagnosis of
antibody deﬁciency in a retrospective analysis.24 Thus,
patients with low IgG2 and IgG4 may suffer from a mild
form of immunodeﬁciency that was previously not recog-
nized in these patients. It is interesting to note that, in 2013,
Karagiannis et al25 described an association between high
IgG4 levels and poor survival in 57 patients diagnosed with
stage I–IV malignant melanoma. However, this study did
not include patients receiving CI therapy.
Low serum IgG levels may result from functional
abnormalities of B cells but also T cells. This is exemplarily
shown in human CTLA4 insufﬁciency, which is thought to
be a T-cell intrinsic defect, associated with antibody deﬁ-
ciency in most patients.26 Subsequent prospective studies are
needed to test B and T-cell intrinsic functions in patients
with normal or low IgG2 levels.
FIGURE 1. Baseline IgG and subclass levels before checkpoint inhibitor treatment in R versus NR. Reference values for total IgG and IgG
subclasses in the white population of matching age to the subjects in this study are as follows: 7.00–16.00 g/L for total IgG; 4.05–
10.11 g/L for IgG1; 1.69–7.86 g/L for IgG2; 0.11–0.85 g/L for IgG3; and 0.03–2.01 g/L for IgG4. IgG indicates immunoglobulin G; NR,
nonresponder; R, responder.
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Elevated IgG2 antibody levels in responders might reﬂect
the presence of speciﬁc antibodies against melanoma self-
antigens such as TRP1, TRP2, and gp100 or the cancer-testis
antigen NY-ESO-1. The presence of these antibodies may,
therefore, be a surrogate marker for inﬂamed tumors.
The following limitations have to be addressed. First, the
relatively small number of patients does not allow us to per-
form extensive multivariable analyses. Nevertheless, our
ﬁndings are statistically signiﬁcant. Second, we do not have
a validation cohort. However, the fact that our study is
FIGURE 2. Progression-free survival depending on baseline serum IgG and IgG subclass levels (below and above cutpoint). HR indicates
hazard ratio; IgG, immunoglobulin G.
FIGURE 3. Overall survival depending on baseline serum IgG and IgG subclass levels (below and above cutpoint). HR indicates hazard
ratio; IgG, immunoglobulin G.
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prospective strengthens the hypothesis that these ﬁndings are
generally applicable.
Furthermore, a certain number of uveal and mucosal
melanoma patients was included, in which CI treatment is
less effective with lower response rates.
In conclusion, serum total IgG and IgG subclass meas-
urements at baseline may serve as biomarkers for checkpoint
inhibitor efﬁcacy in patients with metastatic melanoma. These
ﬁndings are hypothesis generating and have to be conﬁrmed in
prospective studies with larger patient cohorts.
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